List view / Grid view
6 July 2016 | By Victoria White, Digital Content Producer
The EC has extended the current conditional marketing authorisation of Adcetris as consodlidation treatment in post-transplant Hodgkin lymphoma...
6 July 2016 | By Victoria White, Digital Content Producer
Scancell has provided an update from the SCIB1 Phase I/II clinical trial in malignant melanoma, the lead programme from the Company’s ImmunoBody platform...
6 July 2016 | By Victoria White, Digital Content Producer
Medivation has entered into confidentiality agreements with parties that have expressed interest in exploring a potential transaction to acquire the company...
6 July 2016 | By Victoria White, Digital Content Producer
The first subject has been dosed with immuno-oncology candidate HTL1071 in a Phase I clinical study, triggering a US$10 million payment to Heptares...
5 July 2016 | By Victoria White, Digital Content Producer
The six-month study will enrol 60 to 120 Ebola survivors whose semen has evidence of Ebola virus RNA prior to their enrolment...
5 July 2016 | By Victoria White, Digital Content Producer
The approval of Zinbryta is supported by results from two studies, including DECIDE, the largest and longest head-to-head Phase III study ever conducted in MS...
5 July 2016 | By Victoria White, Digital Content Producer
The acquisition gives Bristol-Myers Squibb full rights to Cormorant Pharmaceuticals' HuMax-IL8 antibody programme...
5 July 2016 | By Victoria White, Digital Content Producer
Celltrion is to develop laboratory tests that will enable physicians to identify when patients on an anti-TNF drug require a change of dose...
5 July 2016 | By Victoria White, Digital Content Producer
Cx601 is a suspension of allogeneic adipose-derived stem cells injected intra-lesionally for the treatment of complex perianal fistulas in Crohn’s disease...
4 July 2016 | By Victoria White, Digital Content Producer
Yeliva is a first-in-class, orally-administered sphingosine kinase-2 (SK2) selective inhibitor with anticancer and anti-inflammatory activities...
4 July 2016 | By Victoria White, Digital Content Producer
ESTHER-1 assessed an individualised dosing regimen of follitropin delta compared to follitropin alfa in women undergoing their first cycle of IVF...
4 July 2016 | By Victoria White, Digital Content Producer
The EC has approved a variation to the marketing authorisation for Amgen’s Kyprolis (carfilzomib) to include use in combination with dexamethasone alone...
4 July 2016 | By Victoria White, Digital Content Producer
XBiotech’s Xilonix is the first monoclonal antibody immunotherapy to specifically target and neutralise interleukin-1 alpha (IL-1α)...
4 July 2016 | By Victoria White, Digital Content Producer
Takeda and Altos have entered into an agreement to further the develop Altos’s proprietary compound ATC-1906 for the treatment of gastroparesis...
1 July 2016 | By Victoria White, Digital Content Producer
The US Food and Drug Administration (FDA) has granted a fourth Breakthrough Therapy Designation for ibrutinib (Imbruvica) as monotherapy for the treatment of patients with chronic graft-versus-host-disease (cGVHD) after failure of one or more lines of systemic therapy.
